Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Prima BioMed starts phase I study of IMP-321 for the treatment of melanoma

Jan. 27, 2016

FDA puts Medivation's pidilizumab on clinical hold

Jan. 27, 2016

OncoMed unblinds phase II trial of tarextumab following DSMB analysis

Jan. 26, 2016

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Jan. 25, 2016

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Jan. 25, 2016

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

Jan. 25, 2016

ImmunID to apply its ImmunTraCkeR assay to phase II trial of IRX-2 in HNSCC

Jan. 22, 2016

FDA approves sBLA for Arzerra as extended treatment of recurrent or progressive CLL

Jan. 21, 2016

Mologen and MD Anderson collaborate in trial of lefitolimod + ipilimumab

Jan. 20, 2016

Bayer Schering Pharma announces BUB1 inhibitors

Jan. 15, 2016

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...